Efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favourable intermediate-risk prostate cancer—a protocol for a randomised controlled trial

INTRODUCTION: Prostate cancer (PCa) is men’s second most predominant cancer worldwide. Because the prostate-specific antigen test is used in diagnostics, PCa is more often diagnosed in the early stages, making radical treatment of the disease possible. However, it is estimated that over a million me...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonušas, Justinas, Patasius, Ausvydas, Trakymas, Mantas, Venius, Jonas, Janulionis, Ernestas, Smailyte, Giedre, Kincius, Marius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193050/
https://www.ncbi.nlm.nih.gov/pubmed/37197816
http://dx.doi.org/10.1136/bmjopen-2022-070020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193050/
https://www.ncbi.nlm.nih.gov/pubmed/37197816
http://dx.doi.org/10.1136/bmjopen-2022-070020

Ejemplares similares